Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | YAP1 | P46937 | 1/20 | 0.60 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GPR183 | P32249 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18864777 | 1.00 | TSHR (0.71) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL21593709 | 0.98 | TSHR (0.69) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL30047393 | 0.98 | TSHR (0.69) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL18864671 | 0.86 | TSHR (0.71) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL18864669 | 0.86 | TSHR (0.71) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL13202849 | 0.84 | TSHR (0.69) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL7076837 | 0.84 | TSHR (0.65) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL7076836 | 0.84 | TSHR (0.65) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL4818264 | 0.83 | TSHR (1.00) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL4818267 | 0.83 | TSHR (1.00) | TSHRALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3380101-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200339590-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | eFector Therapautics, Inc. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3380101-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339590-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | TSHR 3587/4885ALDH1A1 4004/4885KMT2A 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.